Please try another search
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Paul S. Anderson | 85 | - | Member of the Scientific and Clinical Advisory Board |
Daniel B. Soland | 68 | 2015 | Independent Director |
Stephen R. Davis | 63 | 2014 | President, CEO & Director |
Arvid Carlsson | 101 | - | Member of the Scientific and Clinical Advisory Board |
Stephen R. Biggar | 53 | 2013 | Independent Chairman of the Board |
Carol A. Tamminga | - | - | Member of the Scientific and Clinical Advisory Board |
Laura A. Brege | 66 | 2008 | Independent Director |
Julian Charles Baker | 57 | 2015 | Independent Director |
Elizabeth A. Garofalo | 65 | 2020 | Independent Director |
Edmund P. Harrigan | 71 | 2015 | Independent Director |
James M. Daly | 62 | 2016 | Independent Director |
Adora Ndu | 43 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review